Table 1.
Baseline clinical and laboratory characteristics of COVID-19 patients with and without PE
| Patients with PE (n = 17) | Controls (n = 1,435) | p value | |
|---|---|---|---|
| Male/female (n/n) (%/%) | 13/4 (76.5/23.5) | 676/759 (47.1/52.9) | 0.016 |
| Age (year) | 66 (21:84) | 58 (18:94) | 0.036 |
| BMI (kg/m2) | 27.54 (22.49:35.80) | 27.56 ± 4.37 | 0.878 |
| Hospitalization time (day) | 17 (4:43) | 8.71 ± 5.50 | <0.001 |
| Leukocyte count/μL | 6,710 (3,990:13,850) | 5,814 ± 2,772 | 0.001 |
| Neutrophil count/μL | 5,290 (2,270:12,400) | 3,410 (710:43,140) | <0.001 |
| Neutrophil percentage (%) | 78.3 (56.9:94.9) | 66.1 ± 12.5 | <0.001 |
| Lymphocyte count/μL | 980 (370:2,560) | 1,370 ± 977 | 0.004 |
| Lymphocyte percentage (%) | 14.8 (3.1:30.1) | 25.6 ± 11.2 | <0.001 |
| NLR | 5.14 (1.89:31.05) | 2.65 (0.16:52.03) | <0.001 |
| PLR | 202.04 (64.45:1397.30) | 155.11 (8.66:3123.08) | 0.006 |
| Hemoglobin (g/dL) | 13.6 (10.0:17.1) | 13.5 ± 1.7 | 0.838 |
| Hematocrit (%) | 40.4 (31.5:50.4) | 41.1 ± 4.6 | 0.915 |
| MCV (80–100 fL) | 89.2 (78.8:95.6) | 86.5 ± 6.6 | 0.301 |
| Platelet count × 103/μL | 195 (119:517) | 200 (13:620) | 0.823 |
| Outcomes (exitus letalis) [(n/total n)/%] | 3/17 (17.6%) | 105/1,435 (7.3%) | 0.107 |
BMI, body mass index; COVID-19, coronavirus disease 2019; MCV, mean corpuscular volume; NLR, neutrophil-to-lymphocyte ratio; PE, pulmonary embolism; PLR, platelet-to-lymphocyte ratio